The expression and action of decay-accelerating factor (CD55) in human malignancies and cancer therapy
| Autor: | Ronald Simon, Burkhard Brandt, Horst Buerger, Kathrin Schier, Jan-Henrik Mikesch, Antje Roetger |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Cancer Research
Cell Review Biology medicine.disease_cause Ligands lcsh:RC254-282 Pathology and Forensic Medicine Metastasis Receptors G-Protein-Coupled Cell surface receptor Antigens CD Neoplasms medicine Humans lcsh:QH573-671 Autocrine signalling Phosphotyrosine Decay-accelerating factor Membrane Glycoproteins CD55 Antigens lcsh:Cytology Cell Biology General Medicine lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Complement system medicine.anatomical_structure Immunology Cancer research Molecular Medicine Carcinogenesis Tyrosine kinase Signal Transduction |
| Zdroj: | Cellular Oncology : the Official Journal of the International Society for Cellular Oncology Scopus-Elsevier Cellular Oncology, Vol 28, Iss 5-6, Pp 223-232 (2006) Europe PubMed Central |
| ISSN: | 1570-5870 |
| Popis: | Decay-accelerating factor (DAF, CD55) is physiologically acting as an inhibitor of the complement system, but is also broadly expressed in malignant tumours. Here DAF seems to exert different functions beyond its immunological role such as e.g. promotion of tumorigenesis, decrease of complement mediated tumor cell lysis, autocrine loops for cell rescue and evasion of apoptosis, neoangiogenesis, invasiveness, cell motility, and metastasis via oncogenic tyrosine kinase pathways and specific seven-span transmembrane receptors (CD97) binding. Therefore, DAF has already become a target for therapy. In this paper we review the role of DAF in human malignancies as described in different basic, diagnostic and experimental therapeutic studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|